Iovance Biotherapeutics, Inc.
IOVA
$3.06
-$0.01-0.33%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -78.56M | -83.54M | -97.10M | -112.98M | -116.38M |
| Total Depreciation and Amortization | 11.69M | 11.15M | 10.86M | 9.91M | 9.71M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 31.56M | 26.74M | 26.52M | 13.34M | 10.81M |
| Change in Net Operating Assets | -37.98M | -13.32M | -38.71M | -32.55M | 11.89M |
| Cash from Operations | -73.30M | -58.97M | -98.43M | -122.28M | -83.97M |
| Capital Expenditure | -4.17M | -2.29M | -442.00K | -4.17M | -3.53M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 0.00 | 0.00 | 0.00 | -52.57M | 253.00K |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 27.85M | -46.51M | 40.66M | -54.76M | -69.57M |
| Cash from Investing | 23.68M | -48.80M | 40.22M | -111.51M | -72.85M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3.19M | 48.23M | 153.83M | 198.28M | 1.15M |
| Repurchase of Common Stock | -880.00K | -6.28M | -1.00M | -4.70M | -186.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2.31M | 41.95M | 152.83M | 193.58M | 962.00K |
| Foreign Exchange rate Adjustments | -1.18M | 1.25M | -125.00K | -491.00K | 3.02M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -48.49M | -64.57M | 94.49M | -40.70M | -152.83M |